-

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.

Suarez will lead the execution of the Company’s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca’s largest single manufacturing investment globally.

The investment underpins AstraZeneca’s goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company’s largest market.

Suarez said: “We are operating at a moment of unprecedented scientific opportunity. Our responsibility is to translate that science into results for patients and for the US healthcare system. By strengthening our US manufacturing and R&D footprint, we will expand access to innovative medicines, create highly skilled jobs, and deliver long-term value.”

Suarez will have full responsibility for AstraZeneca’s US BioPharmaceuticals organization, with accountability for performance, growth and execution across the portfolio.

Suarez brings more than 20 years of experience in the US healthcare sector, with leadership roles spanning commercial, medical and market access functions at AstraZeneca. He returns to the US after serving as Country President for Spain since 2020, where he led one of AstraZeneca’s strongest performing European markets. He expanded Spain’s role in global clinical development and positioned Barcelona as a strategic hub for innovation.

During his tenure in Spain, Suarez established a new global hub in Barcelona and launched the AstraZeneca Healthcare Innovation Hub, committing more than €10 million to digital health and data-driven initiatives focused on translational innovation.

Suarez will be based at AstraZeneca’s US headquarters in Wilmington, Delaware. His appointment is effective immediately.

Biographical information

Rick Suarez was born in the United States and grew up in New Haven, Connecticut. He joined AstraZeneca in 1999 as a pharmaceutical sales specialist and has worked across many functions of the business including marketing, medical affairs and market access.

Notes

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.

Contacts

Media Inquiries
Fiona Cookson +1 212 814 3923

US Media Mailbox: usmediateam@astrazeneca.com

AstraZeneca

NASDAQ:AZN

Release Versions

Contacts

Media Inquiries
Fiona Cookson +1 212 814 3923

US Media Mailbox: usmediateam@astrazeneca.com

More News From AstraZeneca

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-sm...

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired worldwide rights to develop and commercialize ZEGFROVY. ZEGFROVY is approved in the US and China for the 2nd-line treatment of adult pati...

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Toz...
Back to Newsroom